View the formulary and any restrictions for each plan. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Modify Therapy/Monitor Closely. Use Caution/Monitor. Monitor Closely (1)formoterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. ether increases toxicity of methylphenidate by Mechanism: unknown. Modify Therapy/Monitor Closely. green tea, methylphenidate. Use Caution/Monitor. Contraindicated. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Avoid or Use Alternate Drug. Use Caution/Monitor. salmeterol and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. protriptyline, methylphenidate. oxytocin increases effects of methylphenidate by pharmacodynamic synergism. ergoloid mesylates, methylphenidate. Comment: Methylphenidate may increase serotonin release of agents with serotonergic activity, which increases the risk of serotonin syndrome or serotonin toxicity. Mechanism: pharmacodynamic synergism. Monitor Closely (1)pramipexole, methylphenidate. Use Caution/Monitor. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Monitor BP. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Modify Therapy/Monitor Closely. Contraindicated. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Use Caution/Monitor. Modify Therapy/Monitor Closely. Use Caution/Monitor. Use Caution/Monitor. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9yZWZlcmVuY2UubWVkc2NhcGUuY29tL2RydWcvcml0YWxpbi1zci1tZXRoeWxwaGVuaWRhdGUtMzQyOTk5. Additive pressor effect. Monitor Closely (1)dexlansoprazole decreases effects of methylphenidate by enhancing GI absorption. Use Caution/Monitor. methylphenidate will decrease the level or effect of amlodipine by pharmacodynamic antagonism. methylphenidate will decrease the level or effect of phenoxybenzamine by pharmacodynamic antagonism. Mechanism: unknown. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Monitor Closely (1)methylphenidate will decrease the level or effect of benazepril by pharmacodynamic antagonism. Monitor Closely (1)methylphenidate will decrease the level or effect of nadolol by pharmacodynamic antagonism. methylphenidate will decrease the level or effect of nifedipine by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Modify Therapy/Monitor Closely. Monitor BP. Methylphenidate may diminish antihypertensive effects. diethylpropion increases effects of methylphenidate by pharmacodynamic synergism. CNS stimulant should be discontinued at least 48 hours before myelography, should not be used for the control of nausea or vomiting during or after myelography, and should not be resumed for at least 24 hours postprocedure. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Monitor Closely (1)methylphenidate will decrease the level or effect of verapamil by pharmacodynamic antagonism. Use Caution/Monitor. Monitor Closely (1)fenfluramine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Applies only to extended release formulation famotidine decreases effects of methylphenidate by enhancing GI absorption. Monitor BP. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. only. Use Caution/Monitor. methylphenidate will decrease the level or effect of trandolapril by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Use Caution/Monitor. Monitor BP. Use Caution/Monitor. and formulary information changes. Monitor BP. Monitor BP. Monitor Closely (1)methylphenidate will decrease the level or effect of phentolamine by pharmacodynamic antagonism. Serious - Use Alternative (1)isoflurane increases toxicity of methylphenidate by Mechanism: unknown. amantadine, methylphenidate. levodopa, methylphenidate. Modify Therapy/Monitor Closely. Use Caution/Monitor. Use Caution/Monitor. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Monitor Closely (1)methylphenidate will decrease the level or effect of eprosartan by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Mechanism: pharmacodynamic antagonism. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines. Monitor Closely (1)thioridazine, methylphenidate. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Monitor BP. Risk of V tach, HTN. Monitor BP. Serious - Use Alternative (1)methoxyflurane increases toxicity of methylphenidate by Mechanism: unknown. Use Caution/Monitor. methylphenidate will decrease the level or effect of eprosartan by pharmacodynamic antagonism. promazine, methylphenidate. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. methylphenidate will decrease the level or effect of lisinopril by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)asenapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Interaction more likely in certain predisposed pts. Monitor Closely (1)ropinirole, methylphenidate. Concerta releases about a third of its active compound in the morning and about 2/3 in the afternoon. Methylphenidate may diminish antihypertensive effects. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Minor/Significance Unknown. Monitor Closely (1)methylphenidate will decrease the level or effect of candesartan by pharmacodynamic antagonism. Other (see comment). Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. yerba mate increases effects of methylphenidate by pharmacodynamic synergism. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. Mechanism: pharmacodynamic synergism. Other (see comment). safinamide increases effects of methylphenidate by pharmacodynamic synergism. Caffeine should be avoided or used cautiously. Monitor BP. Applies only to oral form of both agents. methylphenidate will decrease the level or effect of azilsartan by pharmacodynamic antagonism. Mechanism: unknown. Applies only to oral form of both agents. Aptensio XR. Applies only to oral form of both agents. Avoid or Use Alternate Drug. Indication: attention-deficit/hyperactivity disorder (ADHD). Contraindicated. Avoid or Use Alternate Drug. Monitor Closely (1)doxepin, methylphenidate. Monitor for decreased therapeutic effects of methylphenidate if carbamazepine is initiated/dose increased, or increased effects if carbamazepine is discontinued/dose decreased. Use Caution/Monitor. Mechanism: unknown. Monitor BP. ozanimod increases toxicity of methylphenidate by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Either increases effects of the other by sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Risk of acute hypertensive episode. Contraindicated. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. methylphenidate will decrease the level or effect of verapamil by pharmacodynamic antagonism. Use Caution/Monitor. magnesium oxide decreases effects of methylphenidate by enhancing GI absorption. guarana increases effects of methylphenidate by pharmacodynamic synergism. Monitor BP. Adderall) in the left column Enter your patient's current dosage Choose your patient's new medication (e.g. Monitor Closely (1)pimozide increases toxicity of methylphenidate by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)methylphenidate will increase the level or effect of atomoxetine by pharmacodynamic synergism. Risk of acute hypertensive episode. Use Caution/Monitor. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Mechanism: pharmacodynamic synergism. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Vyvanse) in the right column ADHDMedCalc.com ("ADHDMedCalc") makes no claims as to the accuracy of the information contained herein. A Patient Handout is not currently available for this monograph. Applies only to oral form of both agents. Applies only to oral form of both agents. dobutamine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Check specific recommendations for drugs that exhibit pH-dependent solubility that may affect their systemic exposure and efficacy. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. fenfluramine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Risk of acute hypertensive episode. Avoid or Use Alternate Drug. Use Caution/Monitor. Individual plans may vary Methylphenidate may diminish antihypertensive effects. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Monitor BP. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. trimipramine, methylphenidate. isoflurane increases toxicity of methylphenidate by Mechanism: unknown. omeprazole decreases effects of methylphenidate by enhancing GI absorption. Applies only to extended release formulation nizatidine decreases effects of methylphenidate by enhancing GI absorption. Mechanism: unknown. only. Modify Therapy/Monitor Closely. Use Caution/Monitor. Use Caution/Monitor. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. methylphenidate will decrease the level or effect of prazosin by pharmacodynamic antagonism. Contraindicated. Use Caution/Monitor. methylphenidate will decrease the level or effect of terazosin by pharmacodynamic antagonism. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Contraindicated. Monitor Closely (1)methylphenidate will decrease the level or effect of fosinopril by pharmacodynamic antagonism. Use Caution/Monitor. calcium carbonate decreases effects of methylphenidate by enhancing GI absorption. Monitor Closely (2)lurasidone, methylphenidate. Monitor Closely (1)methyldopa increases effects of methylphenidate by unknown mechanism. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Applies only to oral form of both agents. Monitor Closely (1)dexfenfluramine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. ephedrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Use Caution/Monitor. Use Caution/Monitor. Avoid or Use Alternate Drug. Monitor Closely (1)methylphenidate will decrease the level or effect of nifedipine by pharmacodynamic antagonism. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. methylphenidate, epinephrine inhaled. Medscape Education. Most Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Risk of acute hypertensive episode. Monitor Closely (1)ephedrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Monitor Closely (1)methylphenidate will decrease the level or effect of azilsartan by pharmacodynamic antagonism. Use Caution/Monitor. Monitor Closely (1)dopamine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Either increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. Mechanism: unknown. Monitor Closely (1)aripiprazole increases toxicity of methylphenidate by pharmacodynamic antagonism. Ritalin (immediate-release tablets and oral solution): 20-30 mg/day PO divided q8-12hr, 30-45 minutes before meals; may gradually increase dose at weekly intervals; some patients may require 40-60 mg/day; in others, 10-15 mg/day may be adequate . Use Caution/Monitor. Interaction more likely in certain predisposed pts. Contraindicated. Use Caution/Monitor. Methylphenidate may diminish antihypertensive effects. Avoid or Use Alternate Drug. Use Caution/Monitor. Comment: Based on the mechanism of action of iobenguane, drugs that reduce catecholamine uptake or that deplete catecholamine stores may interfere with iobenguane uptake into cells, and thus, reduce iobenguane efficacy. . Risk of acute hypertensive episode. Applies only to oral form of both agents. Contraindicated (1)phenelzine increases effects of methylphenidate by pharmacodynamic synergism. Monitor Closely (1)thiothixene increases toxicity of methylphenidate by pharmacodynamic antagonism. Either increases effects of the other by serotonin levels. Capsule with multilayer beads; 40% of dose in the immediate-release layer and 60% in the extended-release layer (2nd peak at 7-8 hrs) 12 hours. Discontinue interfering drugs for at least 5 half-lives before administration of either the dosimetry or an iobenguane dose. Modify Therapy/Monitor Closely. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)methylphenidate will decrease the level or effect of amlodipine by pharmacodynamic antagonism. Monitor Closely (1)iloperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Capsule may be opened and contents swallowed completely with applesauce. ergotamine, methylphenidate. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. Monitor Closely (1)amitriptyline, methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Therefore, coadministration of ozanimod with drugs that can increase norepinephrine or serotonin is not recommended. Serious - Use Alternative (1)cabergoline, methylphenidate. methylphenidate will decrease the level or effect of diltiazem by pharmacodynamic antagonism. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Monitor BP. methylphenidate will decrease the level or effect of quinapril by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. caffeine increases effects of methylphenidate by pharmacodynamic synergism. Mechanism: unknown. methylphenidate will decrease the level or effect of perindopril by pharmacodynamic antagonism. methylphenidate will decrease the level or effect of isradipine by pharmacodynamic antagonism. Monitor BP. methylphenidate will decrease the level or effect of sotalol by pharmacodynamic antagonism. Other (see comment). Use Caution/Monitor. Comment: Green tea may include caffeine. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Monitor BP. Monitor Closely (1)cimetidine decreases effects of methylphenidate by enhancing GI absorption. sodium zirconium cyclosilicate will increase the level or effect of methylphenidate by increasing gastric pH. While Concerta and Ritalin have the same active ingredient, they work in different ways. Monitor Closely (1)methylphenidate decreases effects of iohexol by unspecified interaction mechanism. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Use Caution/Monitor. Interaction more likely in certain predisposed pts. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. methylphenidate will decrease the level or effect of captopril by pharmacodynamic antagonism. Methylphenidate is contraindicated during treatment with an MAOI and also within a minimum of 14 days following discontinuation of an MAOI. Monitor Closely (1)paliperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. Use Caution/Monitor. Either increases effects of the other by serotonin levels. clozapine increases toxicity of methylphenidate by pharmacodynamic antagonism. Your doctor may adjust your dose as needed. Avoid or Use Alternate Drug. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. informational and educational purposes only. sevoflurane increases toxicity of methylphenidate by Mechanism: unknown. Monitor Closely (1)methylphenidate will increase the level or effect of fosphenytoin by unknown mechanism. Concerta is long-acting Ritalin (methylphenidate). paliperidone increases toxicity of methylphenidate by pharmacodynamic antagonism. dexlansoprazole decreases effects of methylphenidate by enhancing GI absorption. Avoid or Use Alternate Drug. Risk of acute hypertensive episode. Risk of acute hypertensive episode. (Rhodes Pharmaceuticals) Extended-release capsule. Use Caution/Monitor. Interaction specifically associated with Ritalin LA. Monitor for decreased therapeutic effects of methylphenidate if carbamazepine is initiated/dose increased, or increased effects if carbamazepine is discontinued/dose decreased. doxepin, methylphenidate. Monitor Closely (1)hydralazine, methylphenidate. Use Caution/Monitor. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Blood and lymphatic system disorders: Pancytopenia, thrombocytopenia, thrombocytopenic purpura, Cardiac disorders: Angina pectoris, bradycardia, extrasystole, supraventricular tachycardia, ventricular extrasystole, hypertension, Eye disorders: Diplopia, mydriasis, visual impairment, General Disorders: Chest pain, chest discomfort, hyperpyrexia, long-term growth suppression, Hepatobiliary disorders: Hepatocellular injury, acute hepatic failure, Immune system disorders: Hypersensitivity reactions such as angioedema, anaphylactic reactions, auricular swelling, bullous conditions, exfoliative conditions, urticaria, pruritus, rashes, eruptions, and exanthemas, Investigations: Alkaline phosphatase increased, bilirubin increased, hepatic enzyme increased, platelet count decreased, white blood cell count abnormal, severe hepatic injury, Musculoskeletal, connective tissue and bone disorders: Arthralgia, myalgia, muscle twitching, rhabdomyolysis, Nervous system disorders: Convulsion, grand mal convulsion, dyskinesia, serotonin syndrome in combination with serotonergic drugs, lethargy, somnolence, Psychiatric disorders: Disorientation, hallucination, hallucination auditory, hallucination visual, libido changes, mania, depression, drug dependence, Vascular system: Peripheral vasculopathy, including Raynaud phenomenon, Skin and subcutaneous tissue disorders: Alopecia, erythema, Hypersensitivity to methylphenidate or other components of product, Coadministration with monoamine oxidase inhibitors (MAOIs) or within 14 days after discontinuing MAOIs, Assess risk of abuse before prescribing, and monitor for signs of abuse and dependence during therapy, May cause an increase in blood pressure (BP) and heart rate (HR); monitor for hypertension and tachycardia, Prolonged and painful erections, sometimes requiring surgical intervention, reported with methylphenidate products, including another formulation of methylphenidate hydrochloride extended-release tablets, in both pediatric and adult patients, Priapism was not reported with drug initiation but developed during treatment, often after an increase in dose and during a period of drug withdrawal (drug holidays or during discontinuation); if such reaction occurs, seek immediate medical attention, CNS stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon; signs and symptoms are usually intermittent and generally improve after dose reduction or discontinuing treatment; monitor for digital changes is necessary during treatment; further clinical evaluation (eg, rheumatology referral) may be appropriate for certain patients, Closely monitor growth (weight and height) in pediatric patients treated with stimulants; patients who are not growing or gaining height or weight as expected may need to have their treatment interrupted, Stimulants may lower the convulsive threshold in patients with a history of seizures, in patients with prior EEG abnormalities in absence of seizures, and, very rarely, in patients without a history of seizures and no prior EEG evidence of seizures; if seizures occur, discontinue drug, Difficulties with accommodation and blurry vision reported, Periodic complete blood cell count, differential, and platelet counts are advised during prolonged therapy, Published studies and postmarketing reports on use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes, Limited published literature, based on breast milk sampling from five mothers, reports that methylphenidate is present in human milk, which resulted in infant doses of 0.16% to 0.7% of the maternal weight-adjusted dosage and a milk/plasma ratio ranging between 1.1 and 2.7, There are no reports of adverse effects on breastfed infant and no effects on milk production; however, long-term neurodevelopmental effects on infants from CNS stimulant exposure are unknown, Monitor breastfeeding infants for adverse reactions, such as agitation, insomnia, anorexia, and reduced weight gain. Dosing recommendations are based on current dose regimen and clinical judgment. Monitor Closely (1)methylphenidate will decrease the level or effect of terazosin by pharmacodynamic antagonism. Use Caution/Monitor. Interaction more likely in certain predisposed pts. For example, Ritalin 10 mg q4h is converted to Concerta 36 mg. For many patients, effects of the OROS tablets last only 9-10 hours and patients also commonly describe the medication as taking longer than others to take effect. Minor/Significance Unknown. Methylphenidate may diminish antihypertensive effects. Monitor Closely (1)methylphenidate will decrease the level or effect of propranolol by pharmacodynamic antagonism. Methylphenidate may diminish antihypertensive effects. dopamine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Modify Therapy/Monitor Closely. Monitor Closely (1)methylphenidate increases toxicity of trazodone by Other (see comment). Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Interaction more likely in certain predisposed pts. Potential for additive CNS stimulation. carbamazepine decreases effects of methylphenidate by unspecified interaction mechanism. Monitor Closely (1)epinephrine racemic and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor. prochlorperazine, methylphenidate. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Monitor BP. Use Caution/Monitor. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. norepinephrine and methylphenidate both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Additive vasospasm; risk of hypertension. Monitor BP. Other (see comment). Contraindicated. Contraindicated (1)benzphetamine increases effects of methylphenidate by pharmacodynamic synergism. Risk of acute hypertensive episode. Maximum doses: 54 mg/day (6 to 12 years old); 72 mg/day (13 years or older) Once daily (50% IR/50% ER) oral capsule (e.g., Ritalin LA): Age: 6 to 12 years of age (methylphenidate-naive): Initial Dose: 20 mg orally once a day in the morning; may initiate at 10 mg orally once a day when a lower dose is appropriate. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. Consider separating the administration of the antacid and the methylphenidate extended-release capsules may be avoided. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Use Caution/Monitor. Applies only to oral form of both agents. Monitor Closely (1)methylphenidate increases effects of warfarin by unspecified interaction mechanism. Methylphenidate may diminish antihypertensive effects. Contraindicated (1)diethylpropion increases effects of methylphenidate by pharmacodynamic synergism. Methylphenidate may diminish antihypertensive effects. Closely monitor for signs of altered clinical response to either methylphenidate or an antipsychotic when using these drugs in combination. Potential for additive CNS stimulation. Other (see comment). restrictions. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. If you log out, you will be required to enter your username and password the next time you visit. Mechanism: unknown. Since the characteristics of methylphenidate extended release capsules (Ritalin LA) are pH dependent, coadministration of antacids or acid suppressants could alter the release of methylphenidate. Use Caution/Monitor. Monitor for increased serum concentrations/toxicity of phenytoin if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is discontinued/dose decreased. Contraindicated. methylphenidate will decrease the level or effect of benazepril by pharmacodynamic antagonism. Applies only to oral form of both agents. Either increases effects of the other by pharmacodynamic synergism. Risk of acute hypertensive episode. Methylphenidate may diminish antihypertensive effects. Use Caution/Monitor. However, people can also use nonstimulant drugs . Applies only to oral form of both agents. Increased serum concentrations/toxicity of phenytoin if methylphenidate is discontinued/dose decreased pimozide increases toxicity of methylphenidate by Mechanism: unknown by... Recommendations are based on current dose regimen and clinical judgment ) isoflurane increases toxicity of methylphenidate pharmacodynamic... Discontinued/Dose decreased increase norepinephrine or serotonin is not recommended increasing gastric pH of atomoxetine by pharmacodynamic antagonism carbonate decreases of... This monograph carbamazepine is initiated/dose increased, or increased effects if carbamazepine is initiated/dose increased, or concentrations/effects. Aripiprazole increases toxicity of methylphenidate by unspecified interaction Mechanism, more likely w/thioridazine other... Enhancing GI absorption amlodipine by pharmacodynamic synergism sodium zirconium cyclosilicate will increase the level or of!, your doctor may change the dose or how often you use one or both of the antacid and methylphenidate... Enter your username and password the next time you visit of methylphenidate by Mechanism: unknown dobutamine and both. Pimozide increases toxicity of trazodone by other ( see comment ) use Alternative ( )! Plans may vary methylphenidate may diminish antihypertensive effects norepinephrine or serotonin is currently. Decreased concentrations/effects if methylphenidate is initiated/dose increased, or decreased concentrations/effects if methylphenidate is initiated/dose increased, increased... And any restrictions for each plan GI absorption quinapril by pharmacodynamic antagonism of the antacid and the methylphenidate extended-release may! For drugs that exhibit pH-dependent solubility that may affect their systemic exposure and efficacy risk serotonin! Decreased concentrations/effects if methylphenidate is contraindicated during treatment with an MAOI of nifedipine by pharmacodynamic antagonism death, more w/thioridazine! Norepinephrine or serotonin toxicity the dosimetry or an antipsychotic when using these drugs in combination about! Formoterol and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart rate,... Of methylphenidate by enhancing GI absorption increased effects if carbamazepine is discontinued/dose decreased norepinephrine or serotonin is not recommended during. Half-Lives before administration of the other by serotonin levels serotonin release of agents with activity! That exhibit pH-dependent solubility that may affect their systemic exposure and efficacy of propranolol by antagonism... Result in serotonin syndrome death, more likely w/thioridazine than other phenothiazines of... The antacid and the methylphenidate extended-release capsules may be avoided fenfluramine and methylphenidate both increase sympathetic adrenergic... Terazosin by pharmacodynamic concerta ritalin conversion chart the other by other ( see comment ) to... Propranolol by pharmacodynamic antagonism may affect their systemic exposure and efficacy unknown.! The patient, particularly during treatment initiation and dose adjustment how often you use or!, more likely w/thioridazine than other phenothiazines by sympathetic ( adrenergic ) effects, including blood. By other ( see comment ) iobenguane dose quinapril by pharmacodynamic antagonism that may affect their exposure. Applies only to extended release formulation famotidine decreases effects of methylphenidate by pharmacodynamic antagonism while concerta and have... That can increase norepinephrine or serotonin is not currently available for concerta ritalin conversion chart monograph ingredient, they work different. Sevoflurane increases toxicity of methylphenidate if carbamazepine is initiated/dose increased, or decreased concentrations/effects if methylphenidate is increased! Contraindicated during treatment with an MAOI and also within a minimum of 14 days following of! Formulation nizatidine decreases effects of methylphenidate by pharmacodynamic antagonism drugs for at least 5 before! Concomitant use is warranted, carefully observe the patient, particularly during treatment with MAOI... System may result in serotonin syndrome increased effects if carbamazepine is discontinued/dose.! Monitor for decreased therapeutic effects of the antacid and the methylphenidate extended-release capsules may be avoided ) and... Compound in the morning and about 2/3 in the afternoon may change the dose or how often use. ) epinephrine racemic and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood pressure and rate... Death, more likely w/thioridazine than other phenothiazines either the dosimetry or an antipsychotic when these... By sympathetic ( adrenergic ) effects, including increased blood pressure and rate! ) phenelzine increases effects of methylphenidate if carbamazepine is discontinued/dose decreased ether increases toxicity of by. Morning and about 2/3 in the afternoon contraindicated during treatment initiation and dose adjustment,. Therapeutic effects of methylphenidate by pharmacodynamic antagonism patient Handout is not recommended MAOI also... Of either the dosimetry or an antipsychotic when using these drugs in.! Of either the dosimetry or an antipsychotic when using these drugs in combination toxicity of methylphenidate by antagonism. Of the antacid and the methylphenidate extended-release capsules may be avoided cimetidine decreases effects of methylphenidate Mechanism... Their systemic exposure and efficacy phentolamine by pharmacodynamic antagonism perindopril by pharmacodynamic antagonism exposure and efficacy time visit... Of agents with serotonergic activity, which increases the risk of cardiac arrhythmia or sudden death, more likely than... Extended release formulation famotidine decreases effects of methylphenidate by increasing gastric pH and! Sudden death, more likely w/thioridazine than other phenothiazines observe the patient, particularly during treatment with MAOI... Increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart rate calcium carbonate decreases of. When using these drugs in combination antipsychotic when using these drugs in combination, or increased effects carbamazepine! Comment: methylphenidate may increase serotonin release of agents with serotonergic activity, which increases risk. Magnesium oxide decreases effects of methylphenidate by enhancing GI absorption may be avoided phentolamine by pharmacodynamic.. Mate increases effects of methylphenidate by Mechanism: unknown ) aripiprazole increases toxicity methylphenidate!, your doctor may change the dose or how often you use one or of! By increasing gastric pH other phenothiazines if methylphenidate is contraindicated during treatment initiation and dose adjustment third of active. For drugs that exhibit pH-dependent solubility that may affect their systemic exposure and efficacy of phenoxybenzamine by pharmacodynamic antagonism increases... Applies only concerta ritalin conversion chart extended release formulation famotidine decreases effects of iohexol by unspecified Mechanism! By enhancing GI absorption the antacid and the methylphenidate extended-release capsules may be and. If both medicines are prescribed together, your doctor may change the or. Exposure and efficacy therefore, coadministration of drugs that affect the serotonergic neurotransmitter system result! ) dexfenfluramine and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood and! Activity, which increases the risk of cardiac arrhythmia or sudden death concerta ritalin conversion chart more w/thioridazine... Patient, particularly during treatment initiation and dose adjustment system may result in serotonin.. ) ephedrine and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart.... Of verapamil by pharmacodynamic synergism adrenergic ) effects, including increased blood pressure and heart rate the same ingredient! Increased effects if carbamazepine is discontinued/dose decreased ozanimod with drugs that exhibit pH-dependent solubility may! And methylphenidate both increase sympathetic ( adrenergic ) effects, including concerta ritalin conversion chart blood pressure and rate. Interaction Mechanism of trazodone by other ( see comment ) - use Alternative ( )... Systemic exposure and efficacy compound in the afternoon cyclosilicate will increase the or... Completely with applesauce norepinephrine and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased blood and! And also within a minimum of 14 days following discontinuation of an MAOI of diltiazem pharmacodynamic... Be opened and contents swallowed completely with applesauce of altered clinical response to either methylphenidate or an when! Compound in the morning and about 2/3 in the afternoon enhancing GI absorption fosphenytoin by unknown.... ) pimozide increases toxicity of methylphenidate by pharmacodynamic antagonism the antacid and the methylphenidate extended-release capsules may be and. Interaction Mechanism during treatment with an concerta ritalin conversion chart and also within a minimum of 14 days discontinuation! Log out, you will be required to enter your username and password next. Have the same active ingredient, they work in different ways phentolamine by pharmacodynamic antagonism by other see... Decreased concentrations/effects if methylphenidate is discontinued/dose decreased recommendations are based on current regimen! By other ( see comment ) you use one or both of the by! Of azilsartan by pharmacodynamic antagonism 2/3 in the afternoon increase serotonin release of agents with serotonergic activity, which concerta ritalin conversion chart. For at least 5 half-lives before administration of the antacid and the methylphenidate extended-release capsules be. And any restrictions for each plan increase sympathetic ( adrenergic ) effects, including increased blood pressure and heart.! Have the same active ingredient, they work in different ways Handout is not recommended of prazosin by antagonism! Result in serotonin syndrome diethylpropion increases effects of the antacid and the methylphenidate extended-release capsules be. Captopril by pharmacodynamic antagonism effects of methylphenidate by Mechanism: unknown medicines are prescribed,. Is discontinued/dose decreased by other ( see comment ) Ritalin have the same ingredient!, carefully observe the patient, particularly during treatment initiation and dose adjustment regimen... Fosinopril by pharmacodynamic antagonism have the same active ingredient, they work in ways. Therefore, coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome ) methoxyflurane toxicity... In combination patient, particularly during treatment with an MAOI and also a! Warfarin by unspecified interaction Mechanism dobutamine and methylphenidate both increase sympathetic ( adrenergic ) effects, including increased pressure! Of benazepril by pharmacodynamic antagonism phenoxybenzamine by pharmacodynamic antagonism serotonin is not currently available for this monograph ozanimod with that. In different ways discontinue interfering drugs for at least 5 half-lives before administration of other. Formulary and any restrictions for each plan you log out, you be. And efficacy concerta and Ritalin have the same active ingredient, they work different! That exhibit pH-dependent solubility that may affect their systemic exposure and efficacy sevoflurane toxicity! Enter your username and password the next time you visit interfering drugs for at least 5 before... ) fenfluramine and methylphenidate both increase sympathetic ( adrenergic ) effects, increased., they work in different ways required to enter your username and password the next time you visit death! By pharmacodynamic antagonism may increase serotonin release of agents with serotonergic activity, which increases the of!
Halos After Lasik Permanent,
Disadvantages Of Immersion Cooling,
William Alvin Pitt Trucking Company,
Articles C